Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Sedor Pharmaceuticals, LLC (Sedor) announced on November 9, 2020 that the U.S. Food and Drug Administration (FDA) has approved SESQUIENT